For clinicians
Retatrutide for prescribers: status, evidence and what FDA has said
A neutral reference. It reports Retatrutide's regulatory status, the quality of its human evidence and what FDA has said about it. It does not suggest a dose, a protocol or a source.
Status reviewed 2026-05-19 · By the Grey Peptides Editorial Board · Regulatory fields generated from our tracker
| Also known as | — |
| FDA approval | Not FDA-approved |
| Compounding (503A) | Investigational (clinical trials only) |
| Outsourcing (503B) | No 503B status recorded |
| WADA 2026 List | Prohibited (S0 catch-all) |
| WADA 2027 List | Prohibited (S0 catch-all) |
| Evidence grade | Medium |
| Status reviewed | 2026-05-19 |
What FDA has said
Retatrutide is investigational: not approved, and available only to people enrolled in its clinical trials. The tracker records it as Investigational (clinical trials only). Anything sold online under its name is outside those trials and has not been reviewed by FDA.
Monitoring: what the literature does and does not say
Retatrutide has no approved label, so there is no labelled monitoring guidance. In the trials, monitoring is defined by each trial's own protocol, which applies to participants in that trial and is not a guide to use outside it. The safety findings reported from the trials so far are in the encyclopedia entry.
Compounding: where it stands
Today's position for Retatrutide: Investigational (clinical trials only). An FDA advisory committee's vote is a non-binding recommendation; until FDA acts, a vote does not change what may be compounded. Our explainer on the 503A and 503B categories sets out what each status means, and the regulatory tracker is updated as FDA acts.
The evidence
A synthetic peptide agonist at GLP-1, GIP, and glucagon receptors, with glucagon agonism adding an energy-expenditure component on top of appetite suppression.
The encyclopedia entry lists the human and animal studies we hold, each with its PMID.
What this page leaves out
Doses, regimens, cycle lengths and sources. That is deliberate. A reference that reports status and evidence is useful only if it is not also a protocol, and for a compound in this position there is no approved one to report.
Sources
- Grey Peptides regulatory tracker, row for Retatrutide, reviewed 2026-05-19. Tracker · dataset
- World Anti-Doping Agency. Prohibited List 2027, dated August 26, 2026, in force January 1, 2027. WADA
This page is a reference for qualified professionals. It is not medical advice, it does not recommend any treatment, and it is not a substitute for the prescriber's own judgement and their state and federal obligations.
Others in this group: CagriSema · Survodutide